Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulotaront in Acutely Psychotic Participants With Schizophrenia
NCT06894212Phase 3Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of ulotaront in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Feb 2025; status: active, not recruiting.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06894212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06894212.